PTC THERAPEUTICS, INC. (PTCT) insider trading

By person

27 insiders · 791 transactions

24.0×

Matthew B. Klein holds 24.0 times base salary in stock. $23.09M of shares against $958.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew B. Klein last reported holding, valued at $60.14, the price Common Stock was last bought or sold at on the open market here, on 14 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Stuart Walter Peltz

Chief Executive Officer

—

$73.94M (115) scheduled

−$73.94M

221,865

$13.34M

+698.3%

Neil Gregory Almstead

Chief Technical Ops Officer

—

$42.26M (139) scheduled

−$42.26M

63,036

$3.79M

+190.1%

Mark Elliott Boulding

Exec. VP and CLO

—

$35.47M (166) scheduled

−$35.47M

105,272

$6.33M

+412.9%

Eric Pauwels

Chief Business Officer

—

$12.63M (71) scheduled

−$12.63M

73,411

$4.41M

+195.0%

Christine Marie Utter

SVP, Chief Accounting Officer

—

$10.93M (80) scheduled

−$10.93M

70,199

$4.22M

+466.7%

Matthew B. Klein

Chief Executive Officer

—

$7.92M (38) scheduled

−$7.92M

383,868

$23.09M

+11,091%

Allan Steven Jacobson

Director

—

$7.08M (23) scheduled

−$7.08M

21,451

$1.29M

+213.2%

Emma Reeve

Director

—

$6.12M (29) scheduled

−$6.12M

10,666

$641.45K

—

Marcio Souza

Chief Operating Officer

—

$5.48M (15) scheduled

−$5.48M

56,841

$3.42M

+34.2%

Michael Schmertzler

Director

$2.32M (2)

$6.71M (22) scheduled

−$4.38M

2,791,454

$167.88M

+1.7%

David P Southwell

Director

—

$3.25M (11) scheduled

−$3.25M

20,850

$1.25M

—

Emily Luisa Hill

Chief Financial Officer

—

$2.86M (24) scheduled

−$2.86M

38,925

$2.34M

+411.8%

Jerome B Zeldis

Director

—

$2.00M (6) scheduled

−$2.00M

22,500

$1.35M

—

Stephanie Okey

Director

—

$1.96M (7) scheduled

−$1.96M

8,000

$481.12K

+242.9%

Glenn Jr Md Phd Steele

Director

—

$1.70M (2) scheduled

−$1.70M

22,500

$1.35M

—

Mary L. Smith

Director

—

$1.43M (2) scheduled

−$1.43M

21,813

$1.31M

—

Lee Scott Golden

EVP & Chief Medical Officer

—

$1.38M (15) scheduled

−$1.38M

79,115

$4.76M

+91.6%

Pierre Gravier

Chief Financial Officer

$198.74K (1)

$971.51K (7) scheduled

−$772.78K

83,986

$5.05M

+5,769%

Alethia Young

Director

—

$464.97K (2) scheduled

−$464.97K

21,067

$1.27M

—

Dawn Svoronos

Director

$337.23K (1)

$101.43K (5)

+$235.80K

29,017

$1.75M

—

Hege Elisabeth Sollie-Zetlmayer

Director

—

52,526

$3.16M

+12.9%

Shane William Charles Kovacs

Chief Financial Officer

—

37,850

$2.28M

+100.8%

Mark Rothera

Chief Commercial Officer

—

33,739

$2.03M

+207.2%

William F. Bell Jr.

Director

—

10,333

$621.43K

—

Jessica Caroline Chutter

Director

—

7,333

$441.01K

—

Tuyen Ong

Chief Medical Officer

—

6,000

$360.84K

—

Complete Pharma Holdings II, LLC entity

10% owner

—

$0.00

−100.0%

No percentages here. This company's share count has moved by a factor of 10.1 over the window, from 8,294,933 to 83,460,802 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

PTC THERAPEUTICS, INC.

What the insiders did Mostly scheduled

By person